DCTs Can Work, But Expect More Time & Costs
Source: Clinical Leader
Dr. Oscar Segurado, the chief medical officer of gene therapy company, ASC Therapeutics, has seen the advantages of a DCT firsthand with his company’s Phase 1 trial, and he talks about the changes he’s had to adapt to when it comes to running these trials.
View the full presentation here.
This website uses cookies to ensure you get the best experience on our website. Learn more